Page 2 - அலை வாழ்க்கை அறிவியல் லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Video Blog Blog Blog 11 May, 2021 Author Etain Lavelle Huntington s disease research suffered a double whammy after Swiss pharmaceutical giant Roche Holding AG halted late-stage trials of an experimental medicine and Wave Life Sciences Ltd. abandoned two drug studies for futility. Roche stopped dosing patients with tominersen after an independent data monitoring committee questioned whether the drug s benefits outweighed its risks. Obviously, it s a very sad situation when we have to stop a pivotal program in a disease like Huntington s where there s such a high unmet need and such a terrible impact on these patients and their families, Bill Anderson, head of Roche s pharmaceuticals business, said on a call with reporters following Roche s first-quarter results. It s a major setback for the field. But we will do everything we can to learn from the work that s been done. And if there s a way forward, we would certainly pursue

South africaUnited kingdomBill andersonRoche andersonPrilenia haydenMichael haydenIsrael teva pharmaceutical industries ltdUniversity of british columbiaVoyager therapeutics incWave life sciences ltdDrug administrationRoche holdingWave life sciencesNetherlands based prilenia therapeuticsTeva pharmaceutical industries ltdSpark therapeutics